BelVitunipharm designated as production site for manufacturing Belarus’ COVID-19 vaccine – ordinance
<p> MINSK, Nov 3 - PrimePress. The pharmaceutical company BelVitunipharm (Vitebsk District) has been designated as a production site, which will host an investment project to arrange for the manufacture of Belarus’ own vaccine against the COVID-2019 coronavirus in 2021-2023. This is specified in a relevant ordinance signed by the president of Belarus on 3 Nov 2021. </p> <p> </p> <p> “This investment project provides for the construction of a vaccine production plant in the village of Dolzha, Vitebsk Oblast (with the upgrade of the existing production facility). The BelVitunipharm premises were chosen by the government, because the company has the necessary infrastructure and competencies to produce a vaccine. In addition to that, it is a promising site to develop a biotechnological cluster. The work on the vaccine is being done by organizations subordinate to the Healthcare Ministry and the National Academy of Sciences. A series of a prototype vaccines has already been developed. </p> <p> </p> <p> The ordinance provides for the exemption of technological equipment, raw materials and materials imported for the implementation of the project from customs duties and the value added tax. </p> <p> </p> <p> As previously reported by the press service of the Belarusian president, Lukashenko said on 7 May 2021 that the country’s own vaccine against COVID-19 had already been obtained “in vitro”. In late July, Belarusian state media reported that a prototype of a domestic vaccine against coronavirus had been created. The development of the prototype was planned to be completed by autumn and put into production in 2022. According to Health Minister Dmitry Pinevich, the Belarusian vaccine against COVID-19 is planned to be released into civilian circulation in 2023. </p> <p> </p> <p> BelVitunipharm OJSC (before 2011 - Vitebsk Biofabrika) is a high-tech biological industry enterprise, a prominent player on the markets of Belarus and the CIS countries. It produces more than 150 items of pharmacological veterinary preparations: sera, viral and bacterial vaccines, medical preparations. The company’s products meet international standards and are exported to Russia, Kazakhstan, Uzbekistan, Armenia, Tajikistan, Turkmenistan, Kyrgyzstan, Bahrain, Kuwait, Egypt and Turkey. End </p>
2021-11-04
Primepress
BelVitunipharm designated as production site for manufacturing Belarus’ COVID-19 vaccine – ordinance
MINSK, Nov 3 - PrimePress. The pharmaceutical company BelVitunipharm (Vitebsk District) has been designated as a production site, which will host an investment project to arrange for the manufacture of Belarus’ own vaccine against the COVID-2019 coronavirus in 2021-2023. This is specified in a relevant ordinance signed by the president of Belarus on 3 Nov 2021.
“This investment project provides for the construction of a vaccine production plant in the village of Dolzha, Vitebsk Oblast (with the upgrade of the existing production facility). The BelVitunipharm premises were chosen by the government, because the company has the necessary infrastructure and competencies to produce a vaccine. In addition to that, it is a promising site to develop a biotechnological cluster. The work on the vaccine is being done by organizations subordinate to the Healthcare Ministry and the National Academy of Sciences. A series of a prototype vaccines has already been developed.
The ordinance provides for the exemption of technological equipment, raw materials and materials imported for the implementation of the project from customs duties and the value added tax.
As previously reported by the press service of the Belarusian president, Lukashenko said on 7 May 2021 that the country’s own vaccine against COVID-19 had already been obtained “in vitro”. In late July, Belarusian state media reported that a prototype of a domestic vaccine against coronavirus had been created. The development of the prototype was planned to be completed by autumn and put into production in 2022. According to Health Minister Dmitry Pinevich, the Belarusian vaccine against COVID-19 is planned to be released into civilian circulation in 2023.
BelVitunipharm OJSC (before 2011 - Vitebsk Biofabrika) is a high-tech biological industry enterprise, a prominent player on the markets of Belarus and the CIS countries. It produces more than 150 items of pharmacological veterinary preparations: sera, viral and bacterial vaccines, medical preparations. The company’s products meet international standards and are exported to Russia, Kazakhstan, Uzbekistan, Armenia, Tajikistan, Turkmenistan, Kyrgyzstan, Bahrain, Kuwait, Egypt and Turkey. End